JNJ

223.6

-1.04%↓

UNH

366.76

+1.31%↑

TMO

472.51

+1.44%↑

ISRG

452.06

+0.37%↑

ABT

86.74

-0.38%↓

JNJ

223.6

-1.04%↓

UNH

366.76

+1.31%↑

TMO

472.51

+1.44%↑

ISRG

452.06

+0.37%↑

ABT

86.74

-0.38%↓

JNJ

223.6

-1.04%↓

UNH

366.76

+1.31%↑

TMO

472.51

+1.44%↑

ISRG

452.06

+0.37%↑

ABT

86.74

-0.38%↓

JNJ

223.6

-1.04%↓

UNH

366.76

+1.31%↑

TMO

472.51

+1.44%↑

ISRG

452.06

+0.37%↑

ABT

86.74

-0.38%↓

JNJ

223.6

-1.04%↓

UNH

366.76

+1.31%↑

TMO

472.51

+1.44%↑

ISRG

452.06

+0.37%↑

ABT

86.74

-0.38%↓

Inicio・Lista de Acciones・MacroGenics Inc

MacroGenics Inc

Abierto

SectorSanidad

2.99 -4.47

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.9699999999999998

Máximo

3.18

Métricas clave
By Trading Economics
Ingresos	-31M -14M
Ventas	-32M 41M
BPA	-0.22
Margen de beneficios	-34.333
Empleados	293
EBITDA	-37M -15M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+97.81% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	81M 203M
Apertura anterior	7.46
Cierre anterior	2.99

Noticias sobre sentimiento de mercado

By Acuity

14%

86%

24 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

1.47 / 1.64 Soporte y Resistencia

MacroGenics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2026, 23:43 UTC

Noticias de Eventos Importantes

New Zealand's Unemployment Rate Falls in 1Q

5 may 2026, 23:20 UTC

Acciones populares

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 may 2026, 21:48 UTC

Ganancias

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 may 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 may 2026, 00:00 UTC

Charlas de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 may 2026, 22:26 UTC

Charlas de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 may 2026, 22:20 UTC

Charlas de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 may 2026, 22:08 UTC

Ganancias

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 may 2026, 22:07 UTC

Ganancias

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Rev $1.2B >PAAS

5 may 2026, 21:42 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:38 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:30 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:29 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:26 UTC

Ganancias

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q EPS 39c >ALC.EB

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 may 2026, 21:24 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:18 UTC

Ganancias

Mistras Backs 2026 Rev $730M-$750M >MG

5 may 2026, 21:17 UTC

Ganancias

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 may 2026, 21:15 UTC

Ganancias

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 may 2026, 21:12 UTC

Ganancias

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 may 2026, 21:11 UTC

Ganancias

SSR Mining 1Q Rev $581.8M >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q EPS $1.16 >SSRM

5 may 2026, 21:08 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:01 UTC

Ganancias

Intact Financial 1Q EPS C$4.12 >IFC.T

5 may 2026, 21:01 UTC

Acciones populares

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparación entre iguales

Cambio de precio

MacroGenics Inc previsión

Precio Objetivo

By TipRanks

97.81% repunte

Estimación a 12 Meses

Media 6.33 USD 97.81%

Máximo 9 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MacroGenics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para MacroGenics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.47 / 1.64Soporte y Resistencia

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

24 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.